Bausch Health, formerly known as Valeant Pharmaceuticals, is a multinational specialty pharmaceutical company with global ...

Vytulta was one of the main reasons that Valeant bought Bausch+Lomb for $8.7 billion in 2013, and the company had originally hoped to get it on the market in the first half of last year.

Valeant Pharmaceuticals is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer. Cramer pointed to the ...

Why not wait to do the deal and let the Bausch & Lomb acquisition annualize to show that it is growing organically? Valeant had, after all, said that it was confident that Bausch & Lomb would ...

Bausch Health is the former Valeant, a company that grew rapidly thanks to a string of acquisitions that left it with $21 billion in debt, almost $10 billion of which will mature in 2027.

Valeant's eye health subsidiary Bausch + Lomb is to work with IBM to develop an app to aid cataract surgeons. The app will be designed to help manage workflow for cataract surgeons by making ...

Ich betreue den optischen Fachhandel incl. der Filialketten und die niedergelassenen Augenärzte in der Region Süd-Hamburg und Niedersachsen. ich habe in dieser Zeit alle Bereiche betreut, also ...

- Vertrieb des gesamten Produktportfolios in der Refraktiven und Katarakt Augenheilkunde - Strategische Planung, Markteinführung neuer Produkte - Erstellung von Umsatz- und Kostenplanung - Einhaltung ...

Simply sign up to the Private equity myFT Digest -- delivered directly to your inbox. Blackstone has cooled on taking part in a joint takeover bid for eyecare company Bausch + Lomb, jeopardising ...